• 1
    Silverman P, Distelhorst CW. Metabolic emergencies in clinical oncology. Semin Oncol. 1989; 16: 504-515.
  • 2
    Jeha S. Tumor lysis syndrome. Semin Hematol. 2001; 38: 4-8.
  • 3
    Hogan DK, Rosenthal LD. Oncologic emergencies in the patient with lymphoma. Semin Oncol Nurs. 1998; 14: 312-320.
  • 4
    Krakoff IH, Meyer RL. Prevention of hyperuricemia in leukemia and lymphoma: use of allopurinol, a xanthine oxidase inhibitor. JAMA. 1965; 193: 1-6.
  • 5
    DeConti RC, Calabresi P. Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med. 1966; 274: 481-486.
  • 6
    Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008; 26: 2767-2778.
  • 7
    Greene ML, Fujimoto WY, Seegmiller JE. Urinary xanthine stones—a rare complication of allopurinol therapy. N Engl J Med. 1969; 280: 426-427.
  • 8
    Andreoli SP, Clark JH, McGuire WA, Bergstein JM. Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr. 1986; 109: 292-298.
  • 9
    Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001; 97: 2998-3003.
  • 10
    Pui CH, Relling MV, Lascombes F, et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia. 1997; 11: 1813-1816.
  • 11
    Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol. 2001; 19: 697-704.
  • 12
    Pui CH, Jeha S, Irwin D, Camitta B. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia. 2001; 15: 1505-1509.
  • 13
    Coiffier B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l”Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol. 2003; 21: 4402-4406.
  • 14
    Pui CH. Rasburicase: a potent uricolytic agent. Expert Opin Pharmacother. 2002; 3: 433-442.
  • 15
    Pui CH, Mahmoud HH, Rivera GK, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood. 1998; 92: 411-415.
  • 16
    Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St. Jude Children's Research Hospital. Blood. 2004; 104: 2690-2696.
  • 17
    Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009; 360: 2730-2741.
  • 18
    Relling MV, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol. 1994; 12: 1667-1672.
  • 19
    Wall AM, Gajjar A, Link A, Mahmoud H, Pui CH, Relling MV. Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. Leukemia. 2000; 14: 221-225.
  • 20
    Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998; 338: 499-505.
  • 21
    Gibaldi M, Perrier D. Multicompartment models. In: GibaldiM, PerrierD, eds. Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker, Inc.; 1982: 45-111.
  • 22
    Stapleton FB, Strother DR, Roy SIII, Wyatt RJ, McKay CP, Murphy SB. Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics. 1988; 82: 863-869.
  • 23
    Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a Pediatric Oncology Group study. J Clin Oncol. 1996; 14: 1252-1261.
  • 24
    Patte C, Sakiroglu C, Ansoborlo S, et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Societe Francaise d”Oncologie Pediatrique LMB-89 protocol. Ann Oncol. 2002; 13: 789-795.
  • 25
    Atra A, Gerrard M, Hobson R, Imeson JD, Ashley S, Pinkerton CR. Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL)—results of the UKCCSG 9003 protocol. Br J Cancer. 1998; 77: 2281-2285.
  • 26
    Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005; 19: 34-38.
  • 27
    Synold TW, Relling MV, Boyett JM, et al. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest. 1994; 94: 1996-2001.
  • 28
    Masson E, Synold TW, Relling MV, et al. Allopurinol inhibits de novo purine synthesis in lymphoblasts of children with acute lymphoblastic leukemia. Leukemia. 1996; 10: 56-60.